Vivoryon (VVY) | Financial Analysis & Statements
Vivoryon Therapeutics N.V. | Small-cap | Healthcare
Vivoryon Therapeutics N.V. | Small-cap | Healthcare
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
0
Gross Profit
0
Operating Income
-21.0M
Net Income
-20.6M
EPS (Diluted)
-€0.79
Balance Sheet Metrics
Total Assets
11.3M
Total Liabilities
3.4M
Shareholders Equity
7.9M
Debt to Equity
0.43
Cash Flow Metrics
Operating Cash Flow
-18.5M
Free Cash Flow
-19.2M
Revenue & Profitability Trend
Vivoryon Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | -3.6M | 0 | 10.8M | 0 |
| Cost of Goods Sold | 0 | -525.0K | 0 | 1.6M | 0 |
| Gross Profit | 0 | -3.1M | 0 | 9.2M | 0 |
| Operating Expenses | 21.0M | 26.2M | 25.1M | 19.9M | 14.7M |
| Operating Income | -21.0M | -28.8M | -29.1M | -12.9M | -16.0M |
| Pre-tax Income | -20.6M | -28.6M | -28.4M | -12.2M | -16.5M |
| Income Tax | 0 | -234.0K | -199.0K | 432.0K | 0 |
| Net Income | -20.6M | -28.3M | -28.2M | -12.7M | -16.5M |
| EPS (Diluted) | -€0.79 | -€1.12 | -€1.28 | -€0.63 | -€0.83 |
Income Statement Trend
Vivoryon Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 10.1M | 29.8M | 30.7M | 20.2M | 28.8M |
| Non-Current Assets | 1.2M | 1.0M | 684.0K | 4.3M | 958.0K |
| Total Assets | 11.3M | 30.8M | 31.4M | 24.5M | 29.8M |
| Liabilities | |||||
| Current Liabilities | 1.4M | 3.2M | 3.3M | 5.1M | 1.3M |
| Non-Current Liabilities | 2.0M | 1.4M | 1.6M | 2.9M | 2.2M |
| Total Liabilities | 3.4M | 4.5M | 4.9M | 8.0M | 3.5M |
| Equity | |||||
| Total Shareholders Equity | 7.9M | 26.3M | 26.5M | 16.6M | 26.2M |
Balance Sheet Composition
Vivoryon Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -20.6M | -28.3M | -28.2M | -12.7M | -16.5M |
| Operating Cash Flow | -18.5M | -22.2M | -19.1M | -15.0M | -14.5M |
| Investing Activities | |||||
| Capital Expenditures | -2.0K | -14.0K | -11.0K | -20.0K | -64.0K |
| Investing Cash Flow | 10.0M | -10.0M | -11.0K | -20.0K | -64.0K |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 0 | 24.3M | 34.2M | 1.1M | 0 |
| Free Cash Flow | -19.2M | -22.1M | -21.8M | -11.3M | -14.7M |
Cash Flow Trend
Vivoryon Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-1.85
Forward P/E
-2.00
Price to Book
4.97
PEG Ratio
-2.00
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-120.41%
Return on Assets
-62.22%
Financial Health
Current Ratio
7.20
Debt to Equity
1.29
Beta
1.98
Per Share Data
EPS (TTM)
-€0.79
Book Value per Share
€0.30
Revenue per Share
€0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| vvy | 39.2M | -1.85 | 4.97 | -120.41% | 0.00% | 1.29 |
| Pharming Group N.V | 637.6M | 57.15 | 2.88 | -6.78% | -4.40% | 55.34 |
| Avantium N.V | 113.2M | -35.65 | 1.17 | -43.03% | -127.72% | 144.79 |
| Aegon | 9.3B | 15.76 | 1.27 | 7.17% | 5.36% | 74.02 |
| Galapagos NV | 1.6B | 51.71 | 0.57 | -6.36% | -58.83% | 0.40 |
| Koninklijke Philips | 18.0B | 74.96 | 1.54 | 1.99% | 2.08% | 64.54 |
Financial data is updated regularly. All figures are in the company's reporting currency.